Table 1.

Clinicopathologic Characteristics by PORT Status

Variable	N (%) or Median (25th, 75th percentile)		P
	PORT (N=69, 70%)	No PORT (N=30; 30%)
Age at surgery (years)	67.0 (57, 71)	65.0 (60, 76)	0.5
Ever smoker
No	11 (16%)	4 (13%)	1.0
Yes	58 (84%)	26 (87%)
Charlson Comorbidity Index	3.0 (2.0, 4.0)	3.0 (2.0, 4.0)	1.0
Cardiac comorbidity
No	36 (52%)	18 (60%)	0.5
Yes	33 (48%)	12 (40%)
Pulmonary comorbiditya
No	50 (72%)	19 (63%)	0.5
Yes	19 (28%)	11 (37%)
Clinical stage before induction therapy
T1–2N2	57 (83%)	27 (90%)	0.5
T3–4N2	12 (17%)	3 (10%)
Pre-induction tumor SUVmax (N=90)	11.3 (6.7, 14.6)	9.3 (5.7, 11.2)	0.03
Treatment effect by pathology
>90%b	5 (7.2%)	1 (3.3%)	0.7
<90%	64 (93%)	29 (97%)
Pneumonectomy
No	68 (98.6%)	27 (90%)	0.08
Yes	1 (1.4%)	3 (10%)
N2 nodal stations examined	2 (2–3)	2 (2–3)	0.7
Lymphovascular invasion (n=96)
No	18 (26%)	12 (43%)	0.15
Yes	50 (74%)	16 (57%)
Number of ypN2 nodal stations involved
Single	48 (70%)	22 (73%)	0.8
Multiple	21 (30%)	8 (27%)
Tumor pathologic subtype
Squamous, large, other	12 (17%)	6 (20%)	0.8
Adenocarcinoma	57 (83%)	24 (80%)
Pathologic tumor stage (ypT)
1a, 1b, 1c	29 (42%)	13 (43%)	0.7
2a, 2b	25 (36%)	11 (37%)
3	11 (16%)	3 (10%)
4	3 (4.3%)	1 (3.3%)
0c	1 (1.4%)	2 (6.7%)
Adjuvant systemic therapy
No	60 (87%)	21 (70%)	0.05
Yes	9 (13%)	9 (30%)
Type of adjuvant systemic therapy (N=18)			0.6
Other systemic therapy (N=8)	5 (56%)	3 (33%)
Tyrosine kinase inhibitor (Erlotinib) (N=10)	4 (44%)	6 (67%)

^aPulmonary comorbidity includes history of tuberculosis, asthma, chronic obstructive pulmonary disease, and/or pulmonary fibrosis, as determined by pulmonary function tests.

^bMajor pathologic response.

^cypT0 tumors had complete response of the primary tumor despite persistent disease present in the N2 nodes.

PORT = postoperative radiotherapy; SUVmax = maximum standardized uptake value.